Skip to content
value.today

Front Range Biosciences, Inc.

Total raised
$43 M
3 rounds on record
Latest round
$19 M
Jan 2020
First round on record
Jul 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Front Range Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2020$19 MNo. 3$10 to $50 million

Front Range Biosciences, Inc.: Raise no. 3, Jan 2020

Investors in this round

55 investors had bought by the notice of Feb 14, 2020: 55 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $40 M offered; $22 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$125,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan Vaught · Executive Officer, Director
  • Nick Hofmeister · Executive Officer, Director
  • Ephraim Lindenbaum · Director
  • Marc Riiska · Director
  • William Militello · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan Vaught, Ceo. Source: SEC Form D, newest notice filed Feb 14, 2020. Read the notice at the SEC.

equitySEC
Jul 2019$9 MNo. 2$2 to $10 million

Front Range Biosciences, Inc.: Raise no. 2, Jul 2019

Investors in this round

55 investors had bought by the notice of Sep 18, 2019: 55 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan Vaught · Executive Officer, Director
  • Nicholas Hofmeister · Executive Officer, Director
  • Ephraim Lindenbaum · Director
  • William Militello · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This filing covers the sale and issuance of Convertible Promissory Notes and the preferred and/or common stock issuable upon conversion.”

Signed by Jonathan Vaught, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 18, 2019. Read the notice at the SEC.

debt, optionsSEC
Jul 2018$16 MNo. 1$10 to $50 million

Front Range Biosciences, Inc.: Raise no. 1, Jul 2018

Investors in this round

87 investors had bought by the notice of Oct 4, 2018: 87 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan Vaught · Executive Officer, Director, Promoter · Founder
  • Nicholas Hofmeister · Executive Officer, Director, Promoter · Founder
  • Douglas Wolford · Director
  • Ephraim Lindenbaum · Director
  • Christopher Zalewski · Promoter · Founder

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nicholas Hofmeister, President/CFO. Source: SEC Form D, newest notice filed Oct 4, 2018. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Front Range Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2020).

    SEC Form D · Feb 2020

  • The industry group it chose in its notices: Other.

    SEC Form D · Feb 2020

That is all the official record says: Front Range Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Front Range Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 87 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Front Range Biosciences, Inc.
NameRoleNamed in
Jonathan VaughtExecutive officerFeb 2020
Nick HofmeisterExecutive officerFeb 2020
Nicholas HofmeisterExecutive officerSep 2019
Ephraim LindenbaumDirectorFeb 2020
Jonathan VaughtDirectorFeb 2020
Marc RiiskaDirectorFeb 2020
Nick HofmeisterDirectorFeb 2020
William MilitelloDirectorFeb 2020
Nicholas HofmeisterDirectorSep 2019
Douglas WolfordDirectorOct 2018
Christopher ZalewskiFounderOct 2018
Jonathan VaughtFounderOct 2018
Nicholas HofmeisterFounderOct 2018